-
New Mpro inhibitors revealed in Vir Biotechnology patent
10 Apr 2025 18:52 GMT
Infection
Work at Vir Biotechnology Inc. has led to the identification of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
BioWorld Science …
-
Holista CollTech sues US company in biotech patent dispute
04 Apr 2025 09:17 GMT
-
Shenzhen Zhongge Biotechnology patents AMP-activated protein kinase α1β1γ1 activators
28 Mar 2025 21:58 GMT
Nephrology
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, …
-
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
21 Apr 2025 20:05 GMT
… is ranked 12th worldwide in biotechnology patent filings and commercial development. Faculty …
-
New KIF18A inhibitors disclosed in Shanghai Apeiron Biotechnology patent
11 Mar 2025 23:24 GMT
Cancer
Shanghai Apeiron Biotechnology Co. Ltd. has divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and Kartagener syndrome (primary ciliary dyskinesia).
BioWorld Science Cancer …
-
AMP-activated protein kinase α1β1γ1 activators disclosed in Shenzhen Zhongge Biotechnology patent
18 Feb 2025 17:23 GMT
Nephrology
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, …
-
AQP4 inhibitors disclosed in Biocells Biotech patent
17 Feb 2025 20:23 GMT
-
Tuojie Biotech patents CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors
10 Feb 2025 17:13 GMT
Cancer
Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially useful for the treatment of cancer, …
-
Shenzhen Zhongge Biotechnology patents new PTPN2 inhibitors
06 Feb 2025 17:36 GMT
-
European Court Invalidates Harvard Biotech Patent in Three Countries
22 Oct 2024 08:24 GMT
A top European court ruled against Harvard last week in a patent dispute against biotech company NanoString Technologies, invalidating one of the University’s two disputed patents in three European countries.
In a 55-page ruling issued by the Central …